AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...